Latest News | Immune Tolerance Network

Pilot Study Seeks to Understand Biomarkers in Cat Allergy Response

The Immune Tolerance Network (ITN) and Imperial College London are collaborating on a new pilot study examining immunological responses to cat allergen. Allergy to cat dander is one of the most common forms of allergic disease in the US and Europe, and can reduce the quality of life for allergy sufferers. The only form of disease-modifying therapy that does not just treat symptoms is immunotherapy, in which cat allergens are administered over a period of time to desensitize a patient.

> read more

Public Launch of ITN TrialShare: The ITN’s New Clinical Trials Research Portal

The ITN is pleased to announce the public launch of ITN TrialShare, its new clinical trials research portal. This system represents a significant leap forward in data sharing and transparency, collaborative hypothesis generation and specimen sharing between the ITN and the broader scientific community.

> read more

HALT-MS Data to be presented at the American Society of Hematology Annual Meeting

Two-year follow-up data from the ITN’s HALT-MS study (High-Dose Immunosuppression and Autologous Transplantation for Multiple Sclerosis) led by Richard Nash, MD (Colorado Blood Cancer Institute) will be presented in an oral abstract at the American Society of Hematology (ASH) annual meeting on December 11^th, 2012 in Atlanta, GA.

> read more

New Publication: Predictors of Peanut Sensitization to Identify Infants at High-Risk for Peanut Allergy

Oral Immunotherapy is known to be an effective means of desensitizing some patients to food allergens, but could the early introduction of foods in high-risk patients prevent allergies altogether?

> read more

In Memory of George Eisenbarth, MD

With deep regret and sadness we note the passing of George Eisenbarth, MD, a member of the ITN family, steering committee, and executive committee since the founding of the network. George was a pioneer in the field of type 1 diabetes research, a great mentor to many, and a wonderful colleague, whose passion for preventing autoimmune diabetes energized us all.

> read more

Data from ITN RAVE Study to be presented at American College of Rheumatology Meeting

Three abstracts from the ITN’s RAVE study (Rituximab for the Treatment of ANCA-associated Vasculitis and Microscopic Polyangiitis) will be presented at the upcoming American College of Rheumatology (ACR) annual meeting in Washington, DC November on 9-14, 2012.

> read more

Type 1 Diabetes Data to be presented at European Association for the Study of Diabetes

Data from three Immune Tolerance Network (ITN) type 1 diabetes studies will be presented at the upcoming European Association for the Study of Diabetes (EASD) meeting on October 1-5, 2012 in Berlin, Germany.

> read more

New Publication: Grass Pollen Nasal Allergen Challenge for Assessing Outcomes

Immune Tolerance Network (ITN) investigators Stephen Durham, MD and Guy Scadding, MD from the Imperial College London conducted a pilot study in collaboration with ALK Abello to evaluate a technique to reproducibly measure time-dependent immunologic responses to allergens using nasal secretion collections. Results from this pilot study are published in the Journal of Immunological Methods [see here].

> read more

New Publication: IL-2 and Rapamycin in Type 1 Diabetes

Results from the IL2-RAPA ITN018AI study, exploring a novel experimental therapy for type 1 diabetes that boosts parts of the healthy immune system, are reported today in the scientific journal Diabetes.

> read more

A View Towards (Immune) Tolerance – Part 5

Detailed below is the fifth and final achievement the Immune Tolerance Network (ITN) recently presented at the Member Society Symposium at the Federation of Clinical Immunology Societies (FOCiS) meeting, and how this work fits in with the broader pursuit of tolerance in transplantation.

> read more